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ABSTRACT Although enteric multianalyte syndromic panels are increasingly em-
ployed, direct comparisons with traditional methods and the inclusion of host phe-
notype correlations are limited. Luminex xTAG gastrointestinal pathogen panel (GPP)
and culture results are highly concordant. However, phenotypic and microbiological
conﬁrmatory testing raises concerns regarding the accuracy of the GPP, especially
for Salmonella spp. A total of 3,089 children with gastroenteritis submitted stool
specimens, rectal swab specimens, and clinical data. The primary outcome was bac-
terial pathogen detection agreement for shared targets between culture and the Lu-
minex xTAG GPP. Secondary analyses included phenotype assessment, additional
testing of GPP-negative/culture-positive isolate suspensions with the GPP, and in-
house and commercial conﬁrmatory nucleic acid testing of GPP-positive/culture-
negative extracts. The overall percent agreement between technologies was 99%
for each pathogen. Salmonella spp. were detected in specimens from 64 partici-
pants: 12 (19%) by culture only, 9 (14%) by GPP only, and 43 (67%) by both tech-
niques. Positive percent agreement for Salmonella spp. was 78.2% (95% conﬁdence
interval [CI], 64.6%, 87.8%). Isolate suspensions from the 12 participants with speci-
mens GPP negative/culture positive for Salmonella tested positive by GPP. Speci-
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mens GPP positive/culture negative for Salmonella originated in younger children
with less diarrhea and more vomiting. GPP-positive/culture-negative specimen ex-
tracts tested positive using additional assays for 0/2 Campylobacter-positive speci-
mens, 0/4 Escherichia coli O157-positive specimens, 0/9 Salmonella-positive speci-
mens, and 2/3 Shigella-positive specimens. For both rectal swab and stool samples,
the median cycle threshold (CT) values, determined using quantitative PCR, were
higher for GPP-negative/culture-positive samples than for GPP-positive/culture-
positive samples (for rectal swabs, 36.9 [interquartile range {IQR}, 33.7, 37.1] versus
30.0 [IQR, 26.2, 33.2], respectively [P 0.002]; for stool samples, 36.9 [IQR, 33.7, 37.1]
versus 29.0 [IQR, 24.8, 30.8], respectively [P 0.001]). GPP and culture have excellent
overall agreement; however, for speciﬁc pathogens, GPP is less sensitive than culture
and, notably, identiﬁes samples false positive for Salmonella spp.
KEYWORDS culture, Salmonella, enteric bacteria, nucleic acid technology,
transmissible gastroenteritis virus
Bacterial enteric pathogens continue to cause substantial morbidity worldwide (1, 2).Although conventional stool culture is classically used to identify bacterial entero-
pathogens in clinical microbiology laboratories, such methods have drawbacks, includ-
ing prolonged turnaround times and a reliance on diverse selective and enrichment
media, identiﬁcation tests, and expertise (3). In contrast, nucleic acid ampliﬁcation
techniques (NAAT) can detect multiple pathogens within hours (4). However, questions
remain about their postmarket accuracy when evaluating a range of enteropathogens
across diverse populations and regions (5). Published data have limited relevance to
North American children, as most reports have emerged from low- and middle-income
countries (5–7), focused primarily on adults (4, 6, 8–12), did not compare NAAT results
to standard culture results (7–10, 13), applied inconsistent testing protocols (4, 8, 11,
14), or analyzed single pathogens (15). No studies have included host phenotypes in
interpreting discordant results.
Here, we determine the agreement for the bacterial pathogens of interest between
stool bacterial culture and the Luminex xTAG gastrointestinal pathogen panel (GPP;
Luminex Molecular Diagnostics, Austin, TX, USA) NAAT platform in a systematically
tested cohort of children with acute gastroenteritis in Alberta, Canada. Secondarily, we
evaluate discordant samples by analyzing clinical phenotypes and determine GPP and
culture accuracy through additional testing.
MATERIALS AND METHODS
Population. This prospective cohort study was conducted as part of the Alberta Provincial Pediatric
EnTeric Infection TEam (APPETITE) project (16). Eligible children were enrolled through the Alberta
Children’s Hospital (Calgary, AB, Canada) and Stollery Children’s Hospital (Edmonton, AB, Canada)
emergency departments (EDs) and a provincial nursing triage telephone advice line (Health Link) (17).
Eligible participants were 18 years of age and had had 3 episodes of vomiting and/or diarrhea in
the preceding 24 h and 7 days of symptoms. Children were excluded if they were enrolled in the
previous 14 days, unable to participate in follow-up, had signiﬁcant psychiatric comorbidities or neutro-
penia, or were critically ill. Children recruited through Health Link did not require medical attention, and
supportive care at home was recommended.
Approval was granted by the University of Calgary and University of Alberta research ethics boards.
Caregivers provided informed consent; assent was obtained when appropriate.
Outcome measures. The primary outcome was agreement, measured as overall percent agreement,
positive percent agreement (PPA), and Cohen’s , between stool bacterial culture and the GPP for
bacterial pathogens sought by both detection methods: Campylobacter spp., Escherichia coli O157,
Salmonella spp., and Shigella spp. Yersinia enterocolitica was not included because of negligible detection
rates.
Secondary outcomes focused on Salmonella spp. and consisted of a comparison of the clinical
phenotypes of patients with concordant and discordant results and three conﬁrmatory tests. First,
GPP-negative/culture-positive isolates were tested using the GPP. Second, an in-house real-time quan-
titative PCR (RT-qPCR) assay was performed on nucleic acid extracts of specimens GPP positive/culture
positive and GPP negative/culture positive for Salmonella spp. to conﬁrm the initial concordant result
and to evaluate the relationship between the cycle threshold (CT) value and pathogen identiﬁcation.
Third, GPP-positive/culture-negative specimens were tested with the in-house RT-qPCR and a different
commercial assay (the Prodesse ProGastro SCSS assay; Hologic Inc., San Diego, CA) (18) on a SmartCycler
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II instrument (Cepheid, Sunnyvale, CA) to conﬁrm or refute the presence of Salmonella spp., Shigella spp.,
and Shiga toxin-producing E. coli (STEC) (see “Conﬁrmatory testing” below for details).
Specimen acquisition. Two rectal swab specimens were obtained from each ED participant
(FLOQSwab; Copan Italia, Brescia, Italy) (19): one was placed in 2 ml of modiﬁed Cary-Blair transport
medium and used for bacterial culture, and the other was placed into a sterile tube without medium and
tested (off-label) using the GPP. Stool samples were collected in sterile containers (V302-F; Starplex
Scientiﬁc Inc., ON, Canada). If they were not provided prior to discharge, stool samples were collected by
the parents at home and placed in the same sterile containers described above, which were retrieved by
a courier service.
Health Link participants received specimen collection kits by courier. Specimens were collected per
ED protocols and were returned to the clinical microbiology laboratory by a study-funded courier service
within 12 h of collection. All specimens were placed in coolers with ice packs while in transit to the
laboratory. Bacterial cultures were inoculated per Public Health Laboratory (ProvLab) protocols as soon
as possible following specimen arrival, after which both the rectal swabs and stool specimens were
stored at 80°C until molecular testing was performed.
Specimen processing. (i) Culture. The FLOQSwab rectal swab specimens were vortexed for 30 s,
and 100 l of transport medium was transferred onto MacConkey agar with crystal violet (Dalynn
Biologicals, Calgary, AB, Canada), sheep blood agar (Oxoid, Thermo Fisher Scientiﬁc, Waltham, MA, USA),
Hektoen agar (Dalynn Biologicals, Calgary, AB, Canada), cefsulodin, irgasan, and novobiocin agar (Dalynn
Biologicals, Calgary, AB, Canada), CHROMagar O157 with 2.5 mg/liter potassium tellurite (CHROMagar,
Paris, France), and Campylobacter blood-free selective agar (Dalynn Biologicals, Calgary, AB, Canada)
plates. Overnight enrichment was performed by adding 200 l of bulk stool to mannitol selenite broth
followed by culture on Salmonella-Shigella (Dalynn Biologicals, Calgary, AB, Canada) and Wilson-Blair
(ProvLab) agar. Campylobacter plates were incubated microaerobically (in 6.0% O2, 7.1% CO2, 3.6% H2,
and 83.3% N2 at 42°C for up to 72 h); all other media were incubated in atmospheric oxygen (35°C, 24 h).
A quantity of stool samples of 1 g was considered insufﬁcient and not subjected to culture. Identiﬁ-
cation of isolates was performed per routine laboratory conﬁrmation protocols using an API 20E system
(bioMérieux Inc., USA) in ProvLab, Calgary, AB, Canada, while a Vitek MS system (bioMérieux, St-Laurent,
QC, Canada) and supplemental biochemical methods were used in ProvLab, Edmonton, AB, Canada.
Salmonella serotyping was performed using the Check & Trace Salmonella assay (Check-Points, Nether-
lands) (20). All positive cultures were skimmed and frozen at 80°C.
(ii) Molecular diagnostics. The GPP is a qualitative multiplex molecular-based syndromic panel that
identiﬁes nine bacterial targets (Campylobacter spp., Clostridioides [formerly Clostridium] difﬁcile toxin A/B,
E. coli O157, enterotoxigenic E. coli [ETEC], Shiga toxin-producing E. coli [STEC] stx1 and stx2, Salmonella
spp., Shigella spp., Vibrio cholerae, Yersinia spp.) (8, 21). GPP testing was performed at a single site
(ProvLab, Edmonton, AB, Canada). Immediately before nucleic acid extraction, stools were thawed and
aliquots were made, and the aliquots were then refrozen at80°C. Rectal swab samples remained frozen
until extraction. Samples were batch tested two to three times a week, depending on specimen volumes.
The FLOQSwab rectal swab specimens were vortexed in 500 l of NucliSENS lysis buffer, and 300 l
of this lysate was added to 700 l of lysis buffer in Bertin SK38 solid grinding lysis bead tubes with 10
l of bacteriophage MS2 (each from Luminex Molecular Diagnostics, Toronto, ON, Canada). Similarly, 100
to 150 mg or 100 l of solid or liquid stool, respectively, was suspended in a ﬁnal volume of 1 ml of lysis
buffer. Two hundred microliters of prepared lysates was extracted using a NucliSENS easyMAG system
(bioMérieux, Marcy l’Etoile, France). Total nucleic acids were eluted in a volume of 70 l and tested per
the recommendations for the xTAG GPP kit. All extracts were stored at 80°C until conﬁrmatory testing.
Conﬁrmatory testing. (i) Testing of GPP-negative/culture-positive Salmonella isolates. Salmo-
nella species isolates were cultured overnight (37°C) on sheep blood agar, and a single colony was
transferred into Bertin SK38 tubes containing 1 ml of NucliSENS lysis buffer. Lysis and extraction were
performed per the recommendations for the testing of stool by the xTAG GPP.
We also performed RT-qPCR using a TaqMan chemistry-based quantitative PCR (qPCR) targeting a
conserved region of the Salmonella invA gene. The forward primer (CTGCGGTACTGTTAATTAC), reverse
primer (GAACGTGGCGATAATTTC), and dual-quenched probe (6-FAM-CGGCATCGG/ZEN/CTTCAATCAAG
A-Iowa Black FQ; where 6-FAM is 6-carboxyﬂuorescein) (Integrated DNA Technologies [IDT], Coralville, IA,
USA) were designed using Beacon Designer (version 8.20) software (Premier Biosoft, Palo Alto, CA, USA).
Five-microliter nucleic acid extracts were used in a 20-l total qPCR volume with 2 PrimeTime gene
expression master mix (IDT, Coralville, IA, USA) with a 0.222 M ﬁnal probe concentration and a 0.333 M
ﬁnal primer concentration. A fast cycling protocol with an initial 95°C polymerase activation step for
3 min, followed by 40 cycles of 95°C for 5 s and 60°C for 30 s, was performed on an Applied Biosystems
7500 Fast instrument. Positive controls with DNA extracted from Salmonella enterica serovar Enteritidis
and no-template controls were integrated into each qPCR run. qPCR assay optimization included
evaluation against a speciﬁcity panel of four clinical Salmonella serotypes (Salmonella Enteritidis, Salmo-
nella Heidelberg, Salmonella Typhimurium, Salmonella Newport), Yersinia enterocolitica (ATCC 9610),
Shigella sonnei (clinical isolate A79), and Shigella ﬂexneri (ATCC 12022).
(ii) RT-qPCR with nucleic acid extracts of GPP-positive/culture-positive specimens. As described
above for GPP-negative/culture-positive Salmonella isolates, we performed RT-qPCR to conﬁrm the result
for GPP-positive/culture-positive specimens and to validate our assay.
(iii) Evaluation of GPP-positive/culture-negative specimens. The frozen DNA extracts used on the
Luminex xTAG GPP were thawed and tested using the Prodesse ProGastro SCSS assay (Hologic Inc., San
Diego, CA) on a SmartCycler II instrument (Cepheid, Sunnyvale, CA) per manufacturer guidelines. The
latter tests for Salmonella, Shigella, and Campylobacter nucleic acids and Shiga toxin 1 and 2 genes (18).
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As described above, we performed RT-qPCR to evaluate specimens GPP positive/culture negative for
Salmonella spp. We performed a similar evaluation for Shigella spp., STEC, and E. coli O157. The primers
and probes used are described in Appendix S1 in the supplemental material.
Statistical analysis. Test results were categorized as positive or negative, with no indeterminant
readings. We did not differentiate between specimen types because rectal swabs have diagnostic
capabilities similar to those of stool samples (19). Only participants whose specimens underwent culture
and GPP testing were analyzed.
Overall percent agreement between the GPP and bacterial culture was determined for the pathogens
of interest (22). For assessing positive response rates, PPA was calculated as [(A)/(A  C)]  100%, where
A is the number of specimens with concordant positive results and C is the number of specimens with
GPP-negative/culture-positive results (22). PPA and overall percent agreement were chosen over sensi-
tivity and speciﬁcity per U.S. Food and Drug Administration guidelines when evaluating diagnostic tests
in the absence of a gold standard (22). Cohen’s  value was calculated to measure the extent of
agreement (23). Clinical characteristics were compared using a chi-square test and the Kruskal-Wallis H
test, as appropriate. The Mann-Whitney U test was used to compare RT-qPCR CT values of the rectal swab
and stool specimen groups GPP positive/culture positive and GPP negative/culture positive for Salmo-
nella spp.
We did not use imputation because data from only seven participants were incomplete; we did
include all available data from these participants in our analysis. SPSS (version 24.0; IBM Corp., Armonk,
NY) was used to perform analyses. A single 2-tailed P value was used to assess differences among all
three groups, and the signiﬁcance level was set at 0.05.
RESULTS
Specimens from 3,089 (88.0%) of the 3,511 participants enrolled between 12 De-
cember 2014 and 31 March 2018 underwent GPP and bacterial culture (Fig. 1).
FIG 1 Flow diagram of potential study participants and enteropathogen detection methods. GPP, gastro-
intestinal pathogen panel.
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Ninety-one (3.0%) and 88 (2.9%) of these specimens, respectively, were positive for at
least one of Campylobacter spp., E. coli O157, Salmonella spp., or Shigella spp.
Primary outcome. The overall percent agreement was 99% for each individual
bacterial target and 98.9% (95% conﬁdence interval [CI], 98.5%, 99.3%) for all targets
combined (Table 1). PPA ranged from 78.2% for Salmonella spp. (95% CI, 64.6%, 87.8%)
to 100% for E. coli O157 (95% CI, 51.7%, 100%). Overall, PPA was 83.0% (73/88; 95% CI,
73.1%, 89.8%). Cohen’s  was 0.70 for E. coli O157, Shigella spp., and Salmonella spp.
and almost perfect for Campylobacter spp. ( 0.89).
Secondary outcomes for Salmonella. The most frequently identiﬁed pathogen,
Salmonella spp., was detected in 64 participants (Fig. 2). Salmonella spp. were detected
in 80% (51/64) of submitted rectal swabs (positive results, n 5 for GPP only, n 12 for
culture only, n 34 for both) and 84% (43/51) of submitted stool specimens (positive
results, n 7 for GPP only, n 8 for culture only, n 28 for both). Salmonella Enteritidis
accounted for 48% (31/64) of the Salmonella spp. identiﬁed by culture (Table 2).
Sixty-seven percent (43/64) of the participants with Salmonella spp. detected in swab
or stool produced concordant GPP and culture test results; 19% (12/64) were GPP
negative/culture positive, and 14% (9/64) were GPP positive/culture negative. Rectal
swabs and stool samples had similar detection rates for Salmonella spp., with the
exception of GPP-positive/culture-negative specimens, where only 33% (3/9) of the
rectal swabs but 88% (7/8) of the stool samples were positive (Table 3).
Participants in the group GPP positive/culture positive for Salmonella spp. were
older (median age, 38 months [interquartile range {IQR}, 13, 63 months]) than those in
the GPP-positive/culture-negative group (median age, 7 months [IQR, 5, 16 months])
(Table 4). The latter group of children had signiﬁcantly more vomiting episodes in the
24 h before enrollment (median, 6 [IQR, 2, 13]) than those with concordant positive
specimens (median, 1 [IQR, 0, 3]) or GPP-negative/culture-positive specimens (median,
1 [IQR, 0, 4]). All 43 GPP-positive/culture-positive specimens were provided by children
who presented with diarrhea; only 44% (4/9) of GPP-positive/culture-negative children
had had diarrhea prior to enrollment (P 0.001). The maximum number of diarrheal
episodes per 24-h period before enrollment was greater in children with specimens
with concordant results (median, 10 [IQR, 7, 15]) than in children with GPP-positive/
culture-negative specimens (median, 0 [IQR, 0, 9]) (P 0.002).
Conﬁrmatory testing. Five of 5 (100%) stool specimens and 8/8 (100%) rectal swab
specimens GPP negative/culture positive for Salmonella isolates were positive by
conﬁrmatory testing by GPP (Fig. 2). Salmonella qPCR of GPP-negative/culture-positive
extracts was positive for 4/12 (25%) rectal swab specimens and 1/5 (20%) stool
specimens. Of the concordant GPP-positive/culture-positive specimens, 36/38 (94.7%)









agreement (95% CI) Cohen’s Positive Negative
Campylobacter spp. Positive 20 2 87.0 (65.3, 96.6) 99.8 (99.6, 99.9) 0.89
Negative 3 3,064
Escherichia coli O157 Positive 6 4 100 (51.7, 100) 99.9 (99.6, 99.9) 0.75
Negative 0 3,079
Salmonella spp. Positive 43 9 78.2 (64.6, 87.8) 99.3 (98.9, 99.6) 0.80
Negative 12 3,025
Shigella spp. Positive 5 3 100 (46.3, 100) 99.9 (99.7, 99.97) 0.77
Negative 0 3,081
Total Positive 73 18 83.0 (73.1, 89.8) 98.9 (98.5, 99.25) 0.81
Negative 15 2,983
aThe bacterial targets included in this table were identiﬁed by both the Luminex xTAG gastrointestinal pathogen panel (GPP) and bacterial culture.
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stool samples and 39/43 (90.7%) rectal swab specimens were positive on qPCR, with
median cycle threshold (CT) values being 29.0 (IQR, 24.8, 30.8) for stool and 30.0 (IQR,
26.2, 33.2) for rectal swabs (P 0.02 for the 32 paired specimens). Median CT values
were higher for GPP-negative/culture-positive than for GPP-positive/culture-positive
Salmonella rectal swab (36.9 [IQR, 33.7, 37.1] versus 30.0 [IQR, 26.2, 33.2]; P 0.002) and
stool specimen extract (36.9 [IQR, 33.7, 37.1] versus 29.0 [IQR, 24.8, 30.8]; P  0.001).
Retesting of GPP-positive/culture-negative specimen extracts yielded the same
results on both the Prodesse ProGastro SCSS and in-house qPCR assays (except for
Campylobacter spp., for which in-house primers were not developed): 0/4 E. coli O157,
0/9 Salmonella species, and 2/3 Shigella species isolates were positive for the bacteria
detected initially on the GPP. Both Campylobacter species-positive specimens were
negative on commercial PCR testing (Table 5).
DISCUSSION
We found excellent overall agreement between the GPP and bacterial culture. For
Salmonella spp., however, GPP-positive/culture-negative children differed signiﬁcantly
from those for whom the results were concordant. Conﬁrmatory analyses demonstrated
that GPP-positive/culture-negative specimens likely are false positive, while GPP-
negative/culture-positive specimens reﬂect the inability of the assay to detect Salmo-
nella spp. when small quantities of nucleic acid are present.
A meta-analysis comparing a variety of multiplex gastrointestinal panels with stan-
dard microbiology methods reported that PPA ranged from 68% when NAAT methods
provide the benchmark to 93% when conventional methods are considered the gold
standard (24). However, the high PPA obtained when conventional methods served as
the benchmark was inconsistent across pathogens, a concern that we identiﬁed as it
FIG 2 Conﬁrmatory testing ﬂow diagram of Salmonella species-positive specimens. All available specimens
were tested. Participants may have submitted both a swab and a stool sample. GPP, gastrointestinal
pathogen panel; qPCR, quantitative PCR; †, GPP-negative/culture-positive samples were not retested with
the commercial assay.
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relates to Salmonella spp. A Vietnamese report identiﬁed a lack of speciﬁcity of
Salmonella species detection using the GPP (5), potentially due to a high rate of
Salmonella carriage (25) or ampliﬁcation of DNA from non-Salmonella strains. In a U.S.
multicenter study, 14% of Salmonella spp. detected by GPP could not be conﬁrmed by
gold standard methods (26).
Given that specimens GPP negative/culture positive for Salmonella had higher CT
values than GPP-positive/culture-positive specimens, our data do not support the
hypothesis that culture fails to detect pathogens because it is less sensitive. While
prolonged storage under suboptimal conditions may permit nucleic acid degradation
(27) and, hence, a lower yield on NAAT platforms, in our study, all samples were
processed within 7 days of receipt and both aliquots and extracts were stored at80°C
at all times. This approach led to our ﬁnding a PPA of 78%, which is aligned with
previous reports (27, 28). While the inability to detect some pathogens on the GPP
could reﬂect inefﬁcient nucleic acid extraction or inhibition, many of the same nucleic
acid extracts yielded positive results with our in-house assay and the alternate platform.
Our RT-qPCR results and our retesting of culture-positive Salmonella isolates on the GPP
lead us to believe that the discrepancies represent a sensitivity threshold, with there
TABLE 2 Serotype analysis of Salmonella species-positive specimens on the Luminex xTAG GPP and bacterial culture
Salmonella serovar








Untyped or nontypeablea 10 (15.6) 9 0 1
Salmonella Agona 1 (1.6) 0 0 1
Salmonella Alachua 1 (1.6) 0 0 1
Salmonella Anatum 1 (1.6) 0 1 0
Salmonella Bareilly 1 (1.6) 0 0 1
Salmonella enterica subsp. enterica 4 (6.3) 0 0 4
Salmonella enterica subsp. salamae (II)55:k:z39 1 (1.6) 0 0 1
Salmonella Enteritidis 31 (48.4) 0 7 24
Salmonella Heidelberg 1 (1.6) 0 0 1
Salmonella Infantis 2 (3.1) 0 1 1
Salmonella Newport 1 (1.6) 0 0 1
Salmonella Reading 2 (3.1) 0 0 2
Salmonella Rubislaw 1 (1.6) 0 0 1
Salmonella Schwarzengrund 1 (1.6) 0 0 1
Salmonella Thompson 1 (1.6) 0 0 1
Salmonella Typhi 1 (1.6) 0 0 1
Salmonella Typhimurium 3 (4.7) 0 2 1
Salmonella Virchow 1 (1.6) 0 1 0
Total 64 (100) 9 (14.1) 12 (18.8) 43 (68.8)
aOf these, isolates were detected in only 9/10 specimens by the Luminex xTAG GPP. The ﬁnal specimen was positive for a Salmonella sp. on GPP and culture, but the
serovar was not identiﬁed.
TABLE 3 Comparison of rectal swab and stool specimen results for Salmonella spp. grouped by diagnostic testing approachb
Salmonella species-positive group Specimen type
No. of specimens with the indicated result/total no. of specimens
tested (%)
Luminex xTAG
GPP positive Culture positive qPCR positive
GPP positive/culture positive Stool 34/38 (89.5) 31/38 (81.6) 36/38 (94.7)
Rectal swab 36/43 (83.7) 38/43 (88.4) 39/43 (90.7)
GPP positive/culture negative Stool 7/8 (87.5)a 0/8 (0) 0/8 (0)
Rectal swab 3/9 (33.3)a 0/9 (0) 0/9 (0)
GPP negative/culture positive Stool 0/5 (0) 5/5 (100) 1/5 (20.0)
Rectal swab 0/12 (0) 8/12 (66.7) 4/12 (33.3)
aP 0.05. No other comparisons achieved statistical signiﬁcance.
bGPP, gastrointestinal pathogen panel; qPCR, quantitative PCR.
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being less target pathogen nucleic acid present in the GPP-negative/culture-positive
group.
The clinical presentations of participants GPP positive/culture negative for Salmonella
spp. were at variance with those of individuals with classic Salmonella infection (29).
Retesting of these specimens using commercial and in-house assays provided negative
results, indicating that the GPP results were likely false positive. All specimens GPP positive/
culture negative for E. coli O157 were also negative when tested with an alternate
commercial and in-house assay, suggesting an overall suboptimal speciﬁcity for these
targets. Concerns regarding false positives due to cross-reactivity with commensal bacteria
have also been reported with the BioFire FilmArray gastrointestinal panel (4). Other possible
causes for false positives on the NAAT include cross contamination, ampliﬁcation of a target
from a non-Salmonella strain, or detection of Salmonella spp. in a child who is a carrier.
Contamination can be addressed by engineering or procedure modiﬁcations, and non-
Salmonella species ampliﬁcation can be minimized by including corroborative loci. For
example, in the case of E. coliO157, the presence of conserved loci for intimin (eae) (30) and
a component of the O157 side chain synthesis cluster (rfbE) (31) increases conﬁdence that
a Shiga toxin gene signal originates in a bona ﬁde pathogen. Nonetheless, these ﬁndings
highlight the concern regarding false-positive results when a multiplex NAAT is employed



















Age (mo)b 43 38 (13, 63) 9 7 (5, 16) 12 31 (11, 66) 0.006
Time since symptom onset (h)b,c 43 84 (45, 102) 9 49 (13, 66) 12 56 (31, 87) 0.05
No. (%) of patients with vomitinga 43 23 (54) 9 7 (78) 12 6 (50) 0.44
Maximum no. of vomiting episodes in any 24-h periodb 43 1 (0, 3) 9 6 (2, 13) 12 1 (0, 4) 0.02
Duration of vomiting at time of enrollment (h)b 43 2 (0, 75) 9 16 (2, 66) 12 0.2 (0, 37) 0.47
No. (%) of patients with diarrheaa 43 43 (100) 9 4 (44) 12 9 (75) 0.001
Maximum no. of diarrhea episodes in any 24-h periodb 43 10 (7, 15) 9 0 (0, 9) 12 7 (1, 12) 0.002
Duration of diarrhea at time of enrollment (h)b 43 83 (37, 101) 9 0 (0, 65) 12 34 (1, 87) 0.02
No. (%) of patients with fevera 43 32 (74) 9 6 (67) 12 6 (50) 0.14
Maximum pain level in prior 24 hb,d 39 7 (5, 8) 7 4 (0, 8) 11 8 (5, 10) 0.15
No. (%) of specimens with non-Salmonella pathogens
presenta,e
43 11 (26) 9 6 (67) 12 3 (25) 0.05
Median (IQR) qPCR CT value
Rectal swab 39 30 (26, 33) 0 NA 4 37 (34, 37) 0.002f
Stool 36 29 (25, 31) 0 NA 1 38 0.05f
aP value by the chi-square test across all three groups.
bP value by the Kruskal-Wallis H test across all three groups.
cDeﬁned by the time of onset of either vomiting or diarrhea, whichever was greater.
dPain level was reported by the parents of the participants on a scale ranging from 0 (no pain at all) to 10 (worst pain imaginable) in the 24 h prior to enrollment
(only for patients enrolled in the emergency departments).
eThis included detection of any of the following targets by GPP, the gastroenteritis virus panel, and/or stool culture in any of the specimens (i.e., swab, stool):
adenovirus, astrovirus, norovirus, rotavirus, sapovirus, Aeromonas, Campylobacter, C. difﬁcile, V. cholerae, E. coli O157, ETEC, Shigella, STEC, Yersinia, Cryptosporidium,
Entamoeba, or Giardia.
fMann-Whitney U test for comparison of two groups.
gGPP, gastrointestinal pathogen panel; qPCR, quantitative PCR; NA, not available.
TABLE 5 Analysis of specimens Luminex xTAG GPP positive/bacterial culture negative for Campylobacter spp., Escherichia coli O157,
Salmonella spp., and Shigella spp. on commercial and in-house PCR assays
Bacteria with positive test result on GPP No. of specimens Commercial assay retest result In-house PCR result
Campylobacter spp. 2 Negative NAa
Escherichia coli O157 4 Negative Negative
Salmonella spp. 9 Negative Negative
Shigella spp. 2 Positive Positive
Shigella spp. 1 Negative Negative
aNA, not applicable (our in-house assay did not include primers for Campylobacter spp.).
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and the importance of considering such results with the clinical presentation and code-
tected pathogens in mind (3, 12).
Although we might be underpowered to detect problems with the identiﬁcation of
E. coli O157 and Shigella spp. by the GPP, the panel identiﬁed all culture-positive
participants. The rapid identiﬁcation of these two pathogens is of considerable value.
Detecting E. coli O157 infection would prompt the withholding or discontinuation of
antibiotics (32) and the reversal of dehydration using parenteral ﬂuids (33–35); the
detection of Shigella would appropriately prompt antibiotic therapy (36, 37). Evidence
supporting this assertion was provided by a study of the BioFire FilmArray GI panel,
which reduced the time to initiation of antimicrobial therapy by 50 h and the time to
the discontinuation of therapy in STEC-infected children by 47 h (12).
Selenite enrichment broth was employed as part of our stool culture protocol to
enhance the identiﬁcation of Salmonella spp. (38). By comparison, false-negative results
by NAAT may relate to technical issues, including nucleic acid extraction efﬁciency. Future
iterations of NAAT-based multianalyte syndromic panels should consider protocol modiﬁ-
cations that enhance diagnostic accuracy, including alternative approaches to extraction,
modiﬁed ampliﬁcation or cycling conditions, and the incorporation of additional pathogen
loci to reduce the number of panel-positive/culture-negative results.
Given our data, the existing literature, and the adjustments required for NAAT
assays, one needs to consider how postmarket monitoring of the performance of
multianalyte assays should be performed. Speciﬁcally, if laboratories abandon culture
detection of enteric pathogens in favor of multianalyte assays, there is little opportunity
to compare recovery rates between the two methodologies. Hence, the failure to detect
pathogens by multianalyte assays will go unveriﬁed. The U.S. Food and Drug Admin-
istration has postmarket surveillance mechanisms for drug safety and efﬁcacy, espe-
cially for those drugs approved via accelerated pathways (39, 40), but no analogous
mechanism exists for diagnostic devices. Our ﬁndings urge continuing assessment of
the accuracy of multianalyte assays for bacterial enteric pathogens.
To our knowledge, this is the ﬁrst study to compare GPP with bacterial culture
employing samples from an entirely pediatric population in a high-income country. It
is also the only study to incorporate the clinical phenotype into the interpretation of
discordant specimens. Our study nonetheless has limitations. Despite our large sample
size, we detected only 64 participants with Salmonella species-positive specimens, and
Campylobacter species-, STEC-, and Shigella species-positive specimens were even less
common. The low prevalence of bacterial enteropathogens has implications for our
reported percent agreement and  calculations. Participants were recruited from only
two western Canadian cities, so our ﬁndings cannot be automatically generalized to
locations with a different epidemiology. We, unfortunately, do not have data to enable
calculation of the precise time interval between specimen receipt at the laboratory and
culture setup. It should also be noted that sampling error may have occurred due to the
small volume of nucleic acid extract used and that all specimens underwent a freeze-
thaw cycle; both of these operational elements could explain negative GPP and qPCR
results in the setting of low bacterial loads.
In conclusion, overall GPP results had excellent concordance with those of bacterial
culture, but the PPA was suboptimal for the shared bacterial targets. In particular,
Salmonella species identiﬁcation with the GPP was prone to false positives and nega-
tives. These results have clinical and public health implications. While the GPP platform
and other NAAT assays have the potential to provide valuable and credible results, their
current accuracy requires additional validation before universal abandonment of cul-
ture diagnostics. Careful consideration of the context of the illness in patients whose
stool tests yield positive results is required.
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